Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28901276 | 0.80 | CHRNB2 (0.54) | CHRNB2CHRNA4LMNACHRNA7HTR3A | |
| SCHEMBL12649101 | 0.80 | CHRNB2 (0.54) | CHRNB2CHRNA4LMNACHRNA7HTR3A | |
| SCHEMBL28901281 | 0.80 | CHRNB2 (0.54) | CHRNB2CHRNA4LMNACHRNA7HTR3A | |
| SCHEMBL2574181 | 0.76 | LMNA (0.49) | MPOLMNAMAPTNPC1RAB9A | |
| SCHEMBL27789344 | 0.75 | HRH1 (0.44) | MPOLMNA | |
| SCHEMBL15211878 | 0.75 | NPC1 (0.40) | PSMB8LMNAMAPTNPC1RAB9A | |
| SCHEMBL31156189 | 0.75 | LMNA (0.40) | MPOPSMB8LMNAMAPTNPC1 | |
| SCHEMBL2202696 | 0.75 | MPO (0.40) | MPOPSMB8LMNAMAPTPRKCZ | |
| SCHEMBL1001293 | 0.75 | MPO (0.56) | MPOLMNAMAPTNPC1RAB9A | |
| SCHEMBL3008510 | 0.74 | BCHE (0.56) | CHRNB2CHRNA4RAB9ASLC6A4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020173505-A1 | Antiserotonine agents; respiratory system disorders; antidepressants; eating disorders | SKOGVALL STAFFAN (SE) | 2002-11-21 | — | — | US | claimed |
| WO-2002036113-A1 | COMPOSITION COMPRISING: SEROTONIN RECEPTOR ANTAGONISTS (5HT-2, 5HT-3) AND AGONIST (5HT-4) | RESPIRATORIUS AB (SE) | 2002-05-10 | — | — | WO | claimed |
| WO-2001095902-A9 | A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND ANTAGONISTS | — | 2002-04-25 | — | — | WO | claimed |
| WO-2001095902-A1 | A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND ANTAGONISTS | RESPIRATORIUS AB (SE) | 2001-12-20 | — | — | WO | claimed |
| CN-109457268-A | A kind of method of electro-catalysis benzamide compound synthesis benzoxazoles | 福建医科大学 | 2019-03-12 | — | — | CN | disclosed |
| CN-109369555-A | A kind of method of microwave radiation benzamide compound synthesis benzoxazoles in water phase | 福建医科大学 | 2019-02-22 | — | — | CN | disclosed |
| EP-1999120-B1 | BENZOTHIAZOLES HAVING HISTAMINE H3 RECEPTOR ACTIVITY | HIGH POINT PHARMACEUTICALS LLC (US) | 2012-06-27 | — | — | EP | disclosed |
| US-7041704-B2 | Methods of treating gastrointestinal tract disorders using sodium channel modulators | DYNOGEN PHARMACEUTICALS, INC. (US) | 2006-05-09 | — | — | US | disclosed |
| EP-1589959-A2 | METHODS OF TREATING LOWER URINARY TRACT DISORDERS USING SODIUM CHANNEL MODULATORS | Dynogen Pharmaceuticals Inc. (US) | 2005-11-02 | — | — | EP | disclosed |
| US-20050203190-A1 | Methods of treating gastrointestinal tract disorders using sodium channel modulators | DYNOGEN PHARMACEUTICALS, INC. (US) | 2005-09-15 | — | — | US | disclosed |
| US-20050107353-A1 | Methods of treating lower urinary tract disorders using losigamone | DYNOGEN PHARMACEUTICALS, INC. (US) | 2005-05-19 | — | — | US | disclosed |
| US-20040213842-A1 | Methods of treating gastrointestinal tract disorders using sodium channel modulators | DYNOGEN PHARMACEUTICALS, INC. | 2004-10-28 | — | — | US | disclosed |
| US-20040209960-A1 | Methods of treating lower urinary tract disorders using sodium channell modulators | DYNOGEN PHARMACEUTICALS, INC. | 2004-10-21 | — | — | US | disclosed |
| WO-2004066990-A2 | METHODS OF TREATING LOWER URINARY TRACT DISORDERS USING SODIUM CHANNEL MODULATORS | DYNOGEN PHARMACEUTICALS, INC. (US) | 2004-08-12 | — | — | WO | disclosed |
| US-20020173505-A1 | Antiserotonine agents; respiratory system disorders; antidepressants; eating disorders | SKOGVALL STAFFAN (SE) | 2002-11-21 | — | — | US | disclosed |
| WO-2002036113-A1 | COMPOSITION COMPRISING: SEROTONIN RECEPTOR ANTAGONISTS (5HT-2, 5HT-3) AND AGONIST (5HT-4) | RESPIRATORIUS AB (SE) | 2002-05-10 | — | — | WO | disclosed |
| WO-2001095902-A9 | A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND ANTAGONISTS | — | 2002-04-25 | — | — | WO | disclosed |
| EP-1173168-A2 | COMPOUND FOR USE AS A MEDICAMENT FOR TREATMENT OF DISORDERS INVOLVING BRONCHOCONTRACTION | Respiratorius AB (SE) | 2002-01-23 | — | — | EP | disclosed |
| WO-2001095902-A1 | A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND ANTAGONISTS | RESPIRATORIUS AB (SE) | 2001-12-20 | — | — | WO | disclosed |
| WO-2000064441-A2 | COMPOUND FOR USE AS A MEDICAMENT FOR TREATMENT OF DISORDERS INVOLVING BRONCHOCONTRACTION | RESPIRATORIUS AB (SE) | 2000-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173505-A1 | Antiserotonine agents; respiratory system disorders; antidepressants; eating disorders | HTR4, HTR2C, HTR5A | MPO 1827/4885CHRNB2 221/4885CHRNA4 72/4885 |
| US-20050203190-A1 | Methods of treating gastrointestinal tract disorders using sodium channel modulators | SLC10A2, TRPV1, VIPR2 | MPO 879/4885CHRNB2 472/4885CHRNA4 302/4885 |
| US-20040213842-A1 | Methods of treating gastrointestinal tract disorders using sodium channel modulators | SLC10A2, VIPR2, TRPV1 | MPO 862/4885CHRNB2 441/4885CHRNA4 292/4885 |
| US-20050107353-A1 | Methods of treating lower urinary tract disorders using losigamone | LPXN, TRPM5, SLC10A2 | MPO 3287/4885CHRNB2 1834/4885CHRNA4 1424/4885 |
| US-20040209960-A1 | Methods of treating lower urinary tract disorders using sodium channell modulators | CACNA1G, CACNA1D, CACNA1B | MPO 1468/4885CHRNB2 365/4885CHRNA4 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.